歌礼制药－B(01672.HK)今日盘中大涨6.6%,引起市场广泛关注。公司公布了其自主研发的ASC30口服片治疗肥胖症患者美国Ia期单剂量递增研究的最新进展。
据了解,该研究显示ASC30口服片整体安全性和耐受性良好,这意味着ASC30口服片有望成为治疗肥胖症的同类最佳小分子口服GLP-1R激动剂。ASC30不仅可每月一次皮下注射,还可每日一次口服用于治疗肥胖症,是目前唯一一款兼具这两种给药方式的小分子GLP-1R激动剂。
分析人士表示,若ASC30口服片最终如期上市,将有望成为全球肥胖症治疗领域新的增长动力,为歌礼制药带来可观收益。因此,ASC30口服片临床研究取得阶段性进展,提振了市场对歌礼制药长期发展前景的信心,成为该股今日大涨的主因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.